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offered screening.
Study design
One could describe this study as a non-randomized trial with historical controls since historical data concerning outcomes when no screening programme is in place were implicitly used for comparison. This was a multi-centre study.
Analysis of effectiveness
The study was based only on those patients completing the various screening rounds and finally undergoing prenatal diagnosis (via amniocentesis). The primary health outcomes were the determination of carrier status among the parents, the detection of a foetus with cystic fibrosis and the rate of termination of foetuses with cystic fibrosis.
Effectiveness results
The probability of a woman choosing to be screened was 0.57. Of the 4,870 women tested, 124 were found to be cystic fibrosis (CF) carriers. Of these 124, 106 partners (85%) were tested. Of these 106 couples, the partner was found to be a carrier in 5 and prenatal diagnosis was chosen by 4 of 5 couples (probability 0.80). Of the 4 couples undergoing prenatal diagnosis, 3 said they would terminate if the foetus was affected (probability 0.75), although, in fact, no foetuses proved to be so affected. Although the effectiveness study found a loss rate from amniocentesis of 20%, this was not used in the calculation as the value was not considered to be representative.
Clinical conclusions
CF carrier status for both partners is rare. CF screening enables couples to determine their carrier status such that decisions concerning diagnosis and potential termination decisions can be made. CF screening is undertaken by approximately half the pregnant women who are offered it.
Modelling
A base model was used in calculating the results, whereby the values of the input variables were subjected to a sensitivity analysis. Modelling was also employed in estimating benefits in the analysis, by way of a decision tree.
Outcomes assessed in the review
Some of the probability estimates used in the economic analysis were derived from sources outside the single study described above, including the probability that the woman or her partner is a carrier, the sensitivity of the screening test and the likelihood that an affected foetus would be replaced.
Study designs and other criteria for inclusion in the review
No criteria were given.
Sources searched to identify primary studies
No information was given on how the studies were found.
Criteria used to ensure the validity of primary studies
No criteria were stated.
Methods used to judge relevance and validity, and for extracting data
No methods were stated. 
Number of primary studies included
Four published sources were used to supplement the data obtained from the primary study. The authors reviewed studies of prenatal cystic fibrosis in a separate publication, indicated at the references of the current paper.
Methods of combining primary studies
Two of the four studies provided data on the same variable (sensitivity of screening test) but were not combined. Instead the study providing the highest value was used as the upper limit in the sensitivity analysis.
Investigation of differences between primary studies
The reason why these two studies gave different results on the sensitivity of the test was not investigated.
Results of the review
The following probabilities, from the above sources, were used in the base-case scenario: sensitivity of screening test 0.85; probability of woman or partner being a carrier 0.04; replacement of affected foetus 1.0.
Methods used to derive estimates of effectiveness
Several of the values used for inputs in the model were derived from the authors' opinions.
Estimates of effectiveness and key assumptions
No references were given for the probability of repeat prenatal diagnosis or the probability of abortion of a second affected foetus. A value of 25% was chosen, based on Mendelian principles, for the probability that the offspring of two CF carriers will be affected with CF. Assumptions used in the model included:
(1) only pregnant women would be offered screening and early enough that prenatal diagnosis could be carried out;
(2) that women are only offered foetal testing if the partner is also identified as a carrier.
The authors stated that they did not consider the risk of a false-positive result in carrier testing and assumed foetal diagnosis to be 100% accurate. Neither did they consider misidentification or unavailability of the partners.
Measure of benefits used in the economic analysis
The authors used QALYs to measure benefits. Additionally, women were asked about their willingness to pay for carrier testing. Utility weights were derived from teenagers with CF (the parents of younger children were asked to give estimates on behalf of their children) using the time trade-off method. In addition all parents were asked about the effect on their life of having a child with CF. All families with CF children cared for in the CF clinic of the University of Rochester Medical Center were invited to participate. In another part of the study, women were asked what they would be willing to pay for the CF screening test.
Direct costs
The study adopted a societal perspective on costs. Therefore indirect care costs, i.e. the cost of the caregivers' time was included alongside the direct medical costs. Costs were discounted at 3%. Quantities and costs were not measured separately. Estimates of the costs were mostly derived from national sources, notably from the Cystic Fibrosis Foundation and the US Congress Office of Technology Assessment. The authors stated that costs arising from the research alone were not included.
which should be adjusted for in the QALYs, and that women found it very difficult to estimate the amount they would be prepared to pay for such a screening test. In conclusion the authors write that the greatest barriers to universal screening were that fewer than one-third of the providers offered screening and that patients were reluctant to accept screening. However, the foremost purpose of parental screening is not to reduce the incidence of genetic disease but to fulfill a couple's reproductive goals.
CRD COMMENTARY -Selection of comparators
The reason for the comparator, i.e. no screening, was clear.
Validity of estimate of measure of benefit
The benefit results would have been more reliable had a comprehensive review of the literature been undertaken in providing data regarding the input variables which could not be obtained from the effectiveness study. More methodological information especially concerning the derivation of the valuation of health states and willingness to pay would have been desirable; and, considering the length of the paper, the could perhaps have been addressed by creating two separate papers. However the authors made their calculations transparent which is an enormous help to others who may wish to insert other probability values, according to their own settings. As the authors themselves admit, intangible costs were not included due to methodological costs in measuring them.
Validity of estimate of costs
The cost data generated by the trial were not considered to be representative, and national data were therefore used instead. The study did not include indirect costs of lost productivity (children and parents) which could have been added into the analysis. However, as with the probabilities on the effectiveness side, all the values used were clearly stated and costs were discounted.
Other issues
As the authors noted, there are still gaps in our knowledge regarding the effect that screening has, most notably with regard to how information on carrier status in the current pregnancy affects future pregnancies.
This was a good and detailed study which admirably attempted to combine many methods of presenting the economic impact of screening into one paper. The authors considered not only the costs and cost savings of such a screening programme, but also combined costs and benefits in terms of a cost-effectiveness study, a cost-utility study and additionally provided data on patients' willingness to pay.
Implications of the study
The authors suggest that their finding of 57% acceptance rate is more reliable than higher rates found in some other studies as it is based on clinical practice. The marginal cost per QALY finding of $8,290 for CF screening compares favourably with that for other widely adopted preventive measures in the USA. 
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